Predict your next investment

HEALTHCARE | Drug Development
adctherapeutics.com

See what CB Insights has to offer

Founded Year

2011

Stage

IPO | IPO

Total Raised

$693M

Date of IPO

5/19/2020

Market Cap

1.66B

Stock Price

29.25

About ADC Therapeutics

ADC Therapeutics (ADCT) is an oncology drug development company that specializes in the development of Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The company's ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca's MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

ADC Therapeutics Headquarter Location

Route de la Corniche 3B

Epalinges, CH-1066,

Switzerland

+41 21 653 02 00

Latest ADC Therapeutics News

Grifols drops $1B on German holding company in continued plasma push

Sep 17, 2021

Josh Sullivan Associate Editor One Span­ish biotech is beef­ing up its plas­ma ther­a­py op­er­a­tions, and on Fri­day, it an­nounced that it’s do­ing so in a bil­lion-dol­lar deal. Gri­fols is now the largest share­hold­er of Biotest, a com­pa­ny val­ued at more than $1.8 bil­lion. By team­ing up, the two will try to in­crease the num­ber of plas­ma ther­a­pies avail­able and in­crease pa­tient ac­cess around the world, Gri­fols said in a press re­lease. The com­pa­ny did so by ac­quir­ing hold­ing com­pa­ny Tiancheng Phar­ma­ceu­ti­cal, the Ger­many-based own­er of near­ly 90% of Biotest shares, for near­ly $1.27 bil­lion. Gri­fols now owns near­ly 90% of Biotest vot­ing rights and al­most 45% of the to­tal share cap­i­tal of Biotest. The move is ex­pect­ed to dri­ve rev­enue growth by more than $8.2 mil­lion by 2024. It will al­low the ex­ist­ing plas­ma-de­rived ther­a­pies in the port­fo­lio to grow, and fast-track the de­vel­op­ment of new ther­a­pies, co-CEO Rai­mon Gri­fols Roura said in a press re­lease. It al­so spreads the com­pa­ny out ge­o­graph­i­cal­ly across the globe, as Biotest is based out of Ger­many, and the com­pa­ny is look­ing to branch its rev­enue stream out across Eu­rope, the Mid­dle East and Africa. “This op­er­a­tion of­fers a sin­gu­lar op­por­tu­ni­ty to pro­mote our Eu­ro­pean in­no­va­tion hub and col­lab­o­rate with an out­stand­ing Ger­man firm renowned for its ex­per­tise in clin­i­cal de­vel­op­ment,” co-CEO Vic­tor Gri­fols Deu said in a press re­lease. “By join­ing forces, we aim to ad­vance in­no­v­a­tive sci­en­tif­ic and plas­ma-de­rived de­vel­op­ments that ul­ti­mate­ly of­fer pa­tients an en­hanced qual­i­ty of life.” The deal will close by the end of Gri­fols’ first se­mes­ter in 2022. Right now, Biotest is in clin­i­cal tri­als on a plas­ma-de­rived fib­rino­gen dubbed BT-524 that will treat con­gen­i­tal and ac­quired dis­or­ders, in­clud­ing an ad­just­ed fib­rino­gen re­place­ment strat­e­gy study in pa­tients who have high blood loss dur­ing spine surgery, and ab­dom­i­nal surgery for pseudomyx­o­ma peri­tonei. The com­pa­ny is al­so in clin­i­cal tri­als for the treat­ment of pa­tients with com­mu­ni­ty-ac­quired pneu­mo­nia. Biotest can man­u­fac­ture up to 1.5 mil­lion liters of plas­ma a year, and it has plans to dou­ble that amount in its 26 Eu­ro­pean sites in Ger­many, the Czech Re­pub­lic and Hun­gary. The move is a part of sev­er­al made to ex­pand Gri­fols foot­print across the globe. In Au­gust, the com­pa­ny an­nounced its sec­ond ex­pan­sion in­to Africa in just a year, as it con­structs an in­tra­venous so­lu­tions plant in Nige­ria. In ear­ly March, the com­pa­ny al­so put up $80 mil­lion to buy out the ma­jor­i­ty stake in Gi­ga­Gen that it didn’t al­ready own. AUTHOR Kyle Blankenship Managing Editor With the first win for its KRAS inhibitor sotorasib in hand, Amgen is pushing ahead with an aggressive clinical plan to capitalize on its first-to-market standing. The drugmaker thinks combinations — in-house or otherwise — could offer a path forward, and one early readout from that strategy is bearing fruit. A combination of Amgen’s sotorasib and its EGFR inhibitor Vectibix posted an overall response rate of 27% in 26 patients with advanced colorectal cancer (CRC) with the KRAS-G12C mutation, according to data from the larger Phase Ib/II CODEBREAK 101 study set to present at this weekend’s virtual ESMO Congress. Keep reading Endpoints with a free subscription Unlock this story instantly and join 117,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Nicole DeFeudis Editor Gilead’s remdesivir — or Veklury, as it’s marketed in the US — raked in around $2.8 billion last year as the only FDA-approved antiviral to treat Covid-19. But new data from a European study suggest the drug, which has been given to about half of hospitalized Covid patients in the country, has no actual benefit. The open-label DisCoVeRy trial enrolled Covid-19 patients across 48 sites in Europe to test a handful of treatments, including remdesivir, lopinavir–ritonavir, lopinavir–ritonavir and interferon beta-1a, and hydroxychloroquine. To participate, patients had to show symptoms for seven days and require oxygen support. A total of 429 patients were randomized to receive remdesivir plus standard of care, while 428 were assigned to standard of care alone. Keep reading Endpoints with a free subscription Unlock this story instantly and join 117,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Senior Editor The FDA released briefing documents this week from the agency and Pfizer each outlining their arguments for today’s Covid-19 booster shot adcomm, but one thing conspicuously missing was the question on which panel members would be voting. But late Thursday night, regulators published that question. Adcomm members will be asked whether or not the safety and efficacy data from Pfizer/BioNTech’s original Phase III study “support approval” of a booster shot at least six months after the second dose in individuals older than 16. The question notably excludes the real-world data from Israel and other analyses that Pfizer and the Biden administration had said would be a centerpiece of their arguments for boosters. Read More Copy/Visuals Editor → Last week we told you about the CMO revolving door at ADC Therapeutics, as Joseph Camardo replaced the departing Jay Feingold. The next opportunity for Feingold in the CMO slot has opened up at antibody-drug conjugate and mAb developer Pyxis Oncology, which has added several new execs and scientific advisory board members in recent months, including ex-Immunovant CFO Pamela Yanchik Connealy. Before his tenure at ADC, Feingold was Daiichi Sankyo’s VP of US medical affairs and chairman of the Global Medical Affairs Oversight Committee. Within weeks in March, Pyxis struck a licensing deal with Pfizer for two of its ADCs and raked in $152 million from a Series B round. Read More Jason Mast Editor About four years ago, Ruben Tommasi, the gregarious scientific chief of antibiotics startup Entasis, walked into a meeting with his top chemist and top biologist to chew over another batch of unchanging results. “It felt like we were running the same experiment over and over,” Tommasi told Endpoints News. “We had all sort of come to that point in time where we felt like we were banging our heads against the wall.” Keep reading Endpoints with a free subscription Unlock this story instantly and join 117,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ADC Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ADC Therapeutics is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

ADC Therapeutics Patents

ADC Therapeutics has filed 240 patents.

The 3 most popular patent topics include:

  • Monoclonal antibodies
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/18/2018

8/10/2021

Experimental cancer drugs, Transcription factors, Monoclonal antibodies, Clusters of differentiation, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/18/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/10/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Experimental cancer drugs, Transcription factors, Monoclonal antibodies, Clusters of differentiation, Proteins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

ADC Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ADC Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.